Pibrentasvir
drugOn this page
Also known as A-1325912.0ABT-530Pibrentasvir component of mavyret
Summary
Pibrentasvir (CHEMBL3545123) is an approved small molecule; indicated across 6 conditions including chronic hepatitis c virus infection and hepatitis c virus infection.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 6 conditions
- Clinical trials: 41
- Chemistry: 1113.2 Da · C57H65F5N10O8
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL3545123 |
| Name | Pibrentasvir |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | no |
| PubChem CID | 58031952 |
| Molecular formula | C57H65F5N10O8 |
| Molecular weight | 1113.2 |
| InChIKey | VJYSBPDEJWLKKJ-NLIMODCCSA-N |
SMILES: C[C@H]([C@@H](C(=O)N1CCC[C@H]1C2=NC3=C(N2)C=C(C(=C3)F)[C@H]4CC[C@@H](N4C5=CC(=C(C(=C5)F)N6CCC(CC6)C7=CC=C(C=C7)F)F)C8=CC9=C(C=C8F)N=C(N9)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)OC)NC(=O)OC)NC(=O)OC)OC
IUPAC name: methyl N-[(2S,3R)-1-[(2S)-2-[6-[(2R,5R)-1-[3,5-difluoro-4-[4-(4-fluorophenyl)piperidin-1-yl]phenyl]-5-[6-fluoro-2-[(2S)-1-[(2S,3R)-3-methoxy-2-(methoxycarbonylamino)butanoyl]pyrrolidin-2-yl]-3H-benzimidazol-5-yl]pyrrolidin-2-yl]-5-fluoro-1H-benzimidazol-2-yl]pyrrolidin-1-yl]-3-methoxy-1-oxobutan-2-yl]carbamate
Also known as: A-1325912.0, ABT-530, Pibrentasvir, Pibrentasvir component of mavyret, PIBRENTASVIR
Patent coverage: 232 distinct patent families (523 SureChEMBL compound mentions), from 4 matched compound structure(s). One matched structure accounts for 514 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Genome polyprotein.
Bioactivity
ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| Q9WMX2 | 9.7 | EC50 | 0.2 | nM | CHEMBL_ACT_18475936 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
6 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| chronic hepatitis C virus infection | 4 | MONDO:0005354 | EFO:0004220 |
| hepatitis C virus infection | 3 | MONDO:0005231 | EFO:0003047 |
| post-traumatic stress disorder | 2 | MONDO:0005146 | EFO:0001358 |
| liver disorder | 1 | MONDO:0005154 | EFO:0001421 |
| kidney disorder | 1 | MONDO:0005240 | EFO:0003086 |
| chronic kidney disease | 0 | MONDO:0005300 | EFO:0003884 |
Clinical trials
Total trials: 41.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 18 |
| PHASE4 | 6 |
| Not specified | 6 |
| PHASE2/PHASE3 | 4 |
| PHASE2 | 3 |
| PHASE1 | 2 |
| PHASE1/PHASE2 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03623568 | PHASE4 | WITHDRAWN | Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant |
| NCT03855917 | PHASE4 | UNKNOWN | Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir |
| NCT04235049 | PHASE4 | WITHDRAWN | Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE) |
| NCT04515797 | PHASE4 | TERMINATED | QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir |
| NCT04575896 | PHASE4 | COMPLETED | Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors |
| NCT05582681 | PHASE4 | TERMINATED | HCV Test and Treat Utilizing Simplified HCV Patient Education |
| NCT05637879 | PHASE2/PHASE3 | RECRUITING | Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder |
| NCT02243293 | PHASE2/PHASE3 | COMPLETED | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection |
| NCT02441283 | PHASE2/PHASE3 | COMPLETED | A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530 |
| NCT02446717 | PHASE2/PHASE3 | COMPLETED | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy |
| NCT02604017 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection |
| NCT02634008 | PHASE3 | COMPLETED | Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P |
| NCT02636595 | PHASE3 | COMPLETED | The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4) |
| NCT02640157 | PHASE3 | COMPLETED | A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection |
| NCT02640482 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection |
| NCT02642432 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis |
| NCT02651194 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection |
| NCT02692703 | PHASE3 | COMPLETED | A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2) |
| NCT02707952 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection |
| NCT02723084 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection |
| NCT02939989 | PHASE3 | COMPLETED | Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study |
| NCT02966795 | PHASE3 | COMPLETED | A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection |
| NCT03069365 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment |
| NCT03089944 | PHASE3 | COMPLETED | A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis |
| NCT03212521 | PHASE3 | COMPLETED | Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1 |
| NCT03219216 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection |
| NCT03222583 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection |
| NCT03235349 | PHASE3 | COMPLETED | Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection |
| NCT07040319 | PHASE1/PHASE2 | RECRUITING | Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV |
| NCT01995071 | PHASE2 | COMPLETED | A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV) |
| NCT02068222 | PHASE2 | COMPLETED | A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection |
| NCT02243280 | PHASE2 | COMPLETED | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection |
| NCT02296905 | PHASE1 | COMPLETED | Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function |
| NCT02442258 | PHASE1 | COMPLETED | Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal Function |
| NCT04682509 | EARLY_PHASE1 | COMPLETED | A Single-center Pilot Study Evaluating a Preemptive Short Course of Glecaprevir/Pibrentasvir in Hepatitis C Positive to Negative Kidney Transplantation |
| NCT03123965 | Not specified | APPROVED_FOR_MARKETING | Expanded Access to Glecaprevir/ Pibrentasvir |
| NCT03492112 | Not specified | COMPLETED | A TEst and Treat Intervention aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgrams |
| NCT03776760 | Not specified | UNKNOWN | Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination |
| NCT03941821 | Not specified | UNKNOWN | Glecaprevir/Pibrentasvir Real-world Study in China |
| NCT03981211 | Not specified | TERMINATED | Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).